**Abstract**

Psychostimulant use disorder exerts profound socioeconomic, legal and medical problems as a primary psychiatric disorder and is a significant comorbid factor for other psychiatric and medical disorders. To date, no medication has been approved by the United States Food and Drug Administration for this indication. In the present Phase 2A, single-site, randomized, double-blind, placebo-controlled clinical trial, we determined the safety/tolerability and efficacy of a combination drug treatment, consisting of an immediate-release methylphenidate formulation (MPh-IR) and a novel formulation of the antiemetic ondansetron (Ond-PR2) (\[MPh-IR + Ond-PR2\]; ClinicalTrials.gov identifier: NCT01290276). Scores on selected behavioral rating scales and functional neuroimaging assessments under standard cue-reactivity and inhibitory control paradigms were used to compare the \[MPh-IR + Ond-PR2\] and placebo groups before and after two week treatment. All study procedures were conducted according to a protocol approved by the Duke University Health System Institutional Review Board. A total of 48 subjects meeting the Diagnostic and Statistical Manual of Mental Disorders Version 4 (DSM-4) criteria for "primary substance abuse" were screened and 30 qualifying subjects were randomized into one of the two treatment groups. Twenty eight subject completed the treatment and pre- and post-treatment assessments. No significant differences were observed between the two groups in the number of subjects experiencing adverse events, and no serious adverse events were observed or reported. In contrast to safety/tolerability, \[MPh-IR + Ond-PR2\] treatment significantly reduced or tended to reduce selected rating score and neuroimaging measurements compared to placebo treatment. In summary, \[MPh-IR + Ond-PR2\] treatment was safe and well-tolerated by abstinent psychostimulant abusers, and the results to date indicate that this treatment might provide for an effective option for psychostimulant abuse treatment.
